Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: A systematic review

Title:	Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: A systematic review
Authors:	Young; KG; McInnes; EH; Massey; RJ; Kahkoska; AR; Pilla; SJ; Raghavan; S; Stanislawski; MA; Tobias; DK; McGovern; AP; Dawed; AY; Jones; AG; Pearson; ER; Dennis; JM; Merino; J; Ahmad; A; Aiken; C; Benham; JL; Bodhini; D; Clark; AL; Colclough; K; Corcoy; R; Cromer; Duan; Felton; Francis; EC; Gillard; P; Gingras; V; Gaillard; Haider; E; Hughes; Ikle; Jacobsen; LM; Kettunen; JLT; Kreienkamp; Lim; L-L; Männistö; JME; McLennan; N-M; Miller; RG; Morieri; ML; Most; Naylor; RN; Ozkan; B; Patel; KA; Prystupa; Raghaven; Rooney; MR; Schön; M; Semnani-Azad; Z; Sevilla-Gonzalez; Svalastoga; Takele; WW; Tam; CH-t; Thuesen; ACB; Tosur; Wallace; AS; Wang; CC; Wong; JJ; Yamamoto; Amouyal; Andersen; MK; Bonham; MP; Chen; Cheng; F; Chikowore; T; Chivers; SC; Clemmensen; Dabelea; Deutsch; AJ; Dickens; LT; DiMeglio; LA; Dudenhöffer-Pfeifer; Evans-Molina; Fernández-Balsells; MM; Fitipaldi; H; Fitzpatrick; SL; Gitelman; SE; Goodarzi; MO; Grieger; JA; Guasch-Ferré; Habibi; N; Hansen; Huang; Harris-Kawano; Ismail; HM; Hoag; Johnson; RK; Koivula; RW; Leong; Leung; GKW; Libman; IM; Liu; Long; SA; Lowe; WL; Morton; Motala; AA; Onengut-Gumuscu; Pankow; JS; Pathirana; Pazmino; Perez; Petrie; JR; Powe; CE; Quinteros; Jain; Ray; Ried-Larsen; Saeed; Santhakumar; Kanbour; Sarkar; Monaco; GSF; Scholtens; DM; Selvin; Sheu; WH-H; Speake; Steenackers; Steck; AK; Stefan; Støy; Taylor; Tye; Ukke; GG; Urazbayeva; Van der Schueren; Vatier; Wentworth; Hannah; W; White; Yu; G; Zhang; Y; Zhou; Beltrand; Polak; Aukrust; I; de Franco; Flanagan; Maloney; Molnes; Nakabuye; Njølstad; PR; Pomares-Millan; Provenzano; Saint-Martin; Zhu; Auh; de Souza; Fawcett; Gruber; Mekonnen; EG; Mixter; Sherifali; Eckel; RH; Nolan; Philipson; LH; Brown; Billings; LK; Boyle; Costacou; Florez; JC; Gloyn; Gomez; MF; Gottlieb; PA; Greeley; SAW; Griffin; Hattersley; AT; Hirsch; IB; Hivert; M-F; Hood; KK; Josefson; Kwak; SH; Laffel; SS; Loos; RJF; Ma; RCW; Mathieu; Mathioudakis; Meigs; JB; Misra; Mohan; Murphy; Oram; Owen; KR; Ozanne; Perng; Pollin; TI; Pop-Busui; Pratley; RE; Redman; Redondo; MJ; Reynolds; RM; Semple; Sherr; Sims; EK; Sweeting; Tuomi; Udler; MS; Vesco; Vilsbøll; Wagner; Rich; Franks; PW; Ada/Easd
Contributors:	Institute of Molecular and Genomic Medicine
Publisher Information:	SPRINGERNATURE
Publication Year:	2023
Collection:	National Health Research Institutes (NHRI): Institutional Repository / 國家衛生研究院機構典藏
Description:	A precision medicine approach in type 2 diabetes requires the identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy.
Document Type:	article in journal/newspaper
File Description:	1068629 bytes; application/pdf
Language:	English
Relation:	Communications Medicine. 2023 Oct 05;3:Article number 131.; http://ir.nhri.org.tw/handle/3990099045/15358; http://ir.nhri.org.tw/bitstream/3990099045/15358/1/NMG2023101311.pdf
DOI:	10.1038/s43856-023-00359-w
Availability:	http://ir.nhri.org.tw/handle/3990099045/15358; https://doi.org/10.1038/s43856-023-00359-w; http://ir.nhri.org.tw/bitstream/3990099045/15358/1/NMG2023101311.pdf
Accession Number:	edsbas.83B82284
Database:	BASE